Evidence by goal

Peptides and energy:
what has been tested?

If you searched for “peptides for energy”, start with what each study measured. This page covers four compounds with published studies in this area: elamipretide (SS-31), NAD+, MOTS-c and humanin. For each: the measure, the model, the number of people or animals, the year and the limit.

Short answerCompound research · 8 min read · Updated 21 Nov 2026

Among elamipretide (SS-31), NAD+, MOTS-c and humanin, the first two have been given to people in trials and the last two have not in any published study we found (November 2026); none is approved in the US as a medicine for low energy or fatigue. In two patient trials, elamipretide did not beat placebo on walking distance or fatigue.

Key takeaways

  • Elamipretide (SS-31) has randomised trials in people: a 2021 study in 39 healthy older adults measured ATP production in a hand muscle, and trials in two patient groups used walking distance and fatigue scores as main measures and did not beat placebo.
  • Elamipretide is the active ingredient of one US medicine, Forzinity, whose label covers muscle strength in adults and children with Barth syndrome weighing at least 30 kg; research-grade material labelled SS-31 is not that medicine.
  • NAD+ is a coenzyme, not a peptide. A 2019 pilot study measured it in the blood and urine of 11 men, and a 2026 analysis pooling four trials of NAD+ and nicotinamide riboside found no significant difference from placebo in its main outcomes, none of them a measure of energy or fatigue, and a rise in a kidney marker with NAD+.
  • No published study we found has given MOTS-c or humanin to people (PubMed and ClinicalTrials.gov, 21 November 2026); the MOTS-c studies that gave it measured treadmill running and energy expenditure in mice.
  • In these studies “energy” is something measured: ATP production, walking distance, a fatigue score, treadmill time or a blood level. The fatigue scores come from trials in patients with genetic conditions, not from healthy people.

01How far has research on peptides and energy gone?

How far the published research has gone for each compound, dated 21 November 2026. Each bar shows the strongest type of study that gave the compound and measured something related to energy. A longer bar means a stronger study design, not a better result. Bar lengths show order only; they are not a score.

Elamipretide (SS-31)
Trials
NAD+
Pilot study
MOTS-c
Mice
Humanin
None found

Elamipretide: randomised trials measured ATP production in muscle, walking distance and fatigue scores. NAD+: a pilot study measured its level in blood and urine. MOTS-c: mouse studies measured treadmill running and energy expenditure. Humanin: the human studies we found measured the body’s own levels, and none gave it to people.

Source: the studies listed in the next section; PubMed and ClinicalTrials.gov searches, 21 Nov 2026.

Is any of them approved for energy or fatigue? No. One of the four is the active ingredient of a US medicine: elamipretide, as Forzinity. Its label says it is “indicated to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg”, under accelerated approval first granted on 19 September 2025. The label says that approval rests on an improvement in knee extensor muscle strength, an intermediate clinical endpoint, and that continued approval may depend on a confirmatory trial. That is not an approval for energy or fatigue, and research-grade material labelled SS-31 is not that medicine. FDA staff wrote in 2026 that MOTS-c is not a component of any FDA-approved drug, and Drugs@FDA lists no product containing NAD+ or humanin (searched 21 November 2026).

02What did each study measure, and in which model?

Each compound, the strongest study we found that gave it and measured something related to energy, and what that study cannot tell you. Dated 21 November 2026. Tiers follow our evidence grades; sources are at the end of the page.

CompoundWhat it isStrongest study with an energy-related measureWhat was measuredTierWhat we don’t know
Elamipretide (SS-31)A four-amino-acid peptide that binds cardiolipin, a fat in the inner membrane of mitochondriaMMPOWER-3, 2023: phase 3, randomised, double-blind, placebo-controlled; 218 adults with primary mitochondrial myopathy; 24 weeks. Also a 2021 randomised, placebo-controlled study in 39 healthy adults aged 60 to 85Distance walked in six minutes and a total fatigue score (2023); peak ATP production in a hand muscle (2021)T1Any effect on energy in healthy people beyond one muscle measure recorded right after a single treatment
NAD+A coenzyme for the redox reactions of energy metabolism; not a peptidePilot study, 2019: 11 healthy men aged 30 to 55, 8 given NAD+ and 3 given salineNAD+ and its breakdown products in blood and urineT2Whether giving NAD+ changes how energetic anyone feels or performs: the pilot measured levels only, and the pooled trials described below report no energy or fatigue measure
MOTS-cA 16-amino-acid peptide encoded in mitochondrial DNAReynolds et al., 2021: mice aged 2, 12 and 22 months, 5 to 19 per group. Lee et al., 2015: male mice on a high-fat diet, N=10 in the paperTreadmill running time and distance (2021); body weight, insulin, energy expenditure and heat production (2015)T3Any effect in people: no published study has given it to people, and the one registered trial has no results
HumaninA peptide encoded in mitochondrial DNAvon Walden et al., 2021: 30 adults randomised to endurance exercise, resistance exercise or no exercise (10 each). Nobody was given humaninThe body’s own humanin and MOTS-c in blood, before and after exerciseT2 (natural levels)Anything about giving humanin to people: we found no study that did

One related molecule appears in the NAD+ row: nicotinamide riboside (NR), which cells convert into NAD+. It is a different molecule, and a trial of NR is not a trial of NAD+.

03What are these compounds, and where was each one tested?

The link between these compounds and “energy” is cell biology. Mitochondria are the compartments that produce most of a cell’s energy. Elamipretide binds a membrane inside them, MOTS-c and humanin are encoded in their DNA, and NAD+ is a coenzyme in the redox reactions of energy metabolism. None of that is a statement about how a person feels.

Human trials · T1

Elamipretide (SS-31)

Binds cardiolipin in the inner membrane of mitochondria, according to its US label. Tested against placebo in people.

Human pilot study · T2

NAD+

A coenzyme for the redox reactions of energy metabolism, not a peptide. A pilot study measured it in blood and urine.

Mice · T3

MOTS-c

A 16-amino-acid peptide encoded in mitochondrial DNA. The studies that gave it used mice and cells.

More on each: SS-31 (elamipretide), NAD+ and MOTS-c.

04What have studies in people measured?

Two of the four have been given to people in published studies: elamipretide and NAD+. We report what each study measured and whether it met its main goal.

Elamipretide: ATP production in older adults (T1, small, n=39). A randomised, double-blind, placebo-controlled study gave a single treatment to 39 healthy adults aged 60 to 85, enrolled for poorly functioning mitochondria, and measured peak ATP production in a hand muscle by magnetic resonance spectroscopy. Right after treatment the change versus placebo was borderline (p=0.055 for the absolute change, p=0.045 for the percentage change). On day 7 there was no difference, and resistance to fatigue in the same muscle did not change. The developer, Stealth BioTherapeutics, funded the study.

Elamipretide: walking distance and fatigue in patients (T1). The phase 3 MMPOWER-3 trial randomised 218 adults with genetically confirmed primary mitochondrial myopathy to elamipretide or placebo for 24 weeks. Its primary endpoints were the distance walked in six minutes and a total fatigue score; it met neither. In the crossover trial on the US label, 12 males aged 12 to 35 with Barth syndrome received elamipretide and placebo in a random sequence. The primary endpoints were again a six-minute walk and a fatigue score, and the label says the medicine “was not superior to placebo” on them.

NAD+: levels in blood and urine (T2, n=11). A 2019 pilot study gave NAD+ to 8 healthy men aged 30 to 55 and saline to 3, and measured NAD+ and its breakdown products in their blood and urine. It measured levels, not how anyone felt or performed. It was funded jointly by a company and a research institute; one author is a director of that company and medical director of the clinic where the study was run.

NAD+ and a precursor, pooled (T1, small trials). A systematic review and meta-analysis published on 17 November 2026 pooled four randomised, placebo-controlled trials in 387 adults with symptomatic heart failure who were on standard treatment. The trials tested NAD+ or nicotinamide riboside (NR). The primary outcomes were heart-failure hospital admissions, deaths from any cause and left ventricular ejection fraction, the share of blood the heart pumps out with each beat. None differed significantly from placebo. Nor did measures of heart size and strain, NT-proBNP (a blood marker of heart strain) or ALT (a liver marker). Serum creatinine, a kidney marker, rose with NAD+ (two trials, 209 people). The authors wrote that the treatments “appeared generally well tolerated in the short term”, but that the creatinine rise “warrants further evaluation”. The abstract reports no measure of energy or fatigue.

A precursor on its own: NR (T1, small, n=24). A 2018 randomised, placebo-controlled crossover trial in healthy adults aged 55 to 79, which 24 completed, measured NAD+ in blood cells after six weeks of NR and after six weeks of placebo. The level was higher after NR. In the same trial, energy expenditure, VO2max and treadmill time to exhaustion did not differ from placebo. A higher level in blood cells is a lab value, not an outcome.

What a 2026 systematic review concluded. A review of human and rodent studies of NAD+ and its precursors, covering January 2010 to October 2025, included 33 human studies, 28 of them randomised. In people, it found that NR and NMN by mouth changed NAD-related measures in blood or blood cells, while effects on functional and other health-related outcomes were “heterogeneous and often null or endpoint-specific”. One of its two authors declared owning a company that provides administrative services to an aesthetics clinic, which the declaration says offers no NAD+ products or treatments.

We describe designs and measures, and report null results in full. Why we never state amounts: our policy.

05What have MOTS-c and humanin studies measured, and in which models?

The studies that gave MOTS-c used mice and cells. We describe the models and what was measured, not the authors’ findings. Animal results are not evidence of an effect in people.

MOTS-c: energy expenditure in mice (T3). The 2015 paper that described MOTS-c, a 16-amino-acid peptide encoded in mitochondrial DNA, gave it to male mice on a high-fat diet (N=10 in the paper). It recorded body weight, food intake, glucose and insulin, and measured energy expenditure, heat production and activity.

MOTS-c: treadmill running in mice (T3). In 2021 the same research group measured treadmill running time and distance in mice aged 2, 12 and 22 months, in groups of 5 to 19, and grip strength, stride length and a 60-second walking test in old mice. Two of the authors declared consulting roles and shares in CohBar, Inc.

MOTS-c in people: natural levels only (T2). In the same 2021 paper, 10 young men cycled and researchers measured the MOTS-c their own bodies made, in muscle and blood. A 2021 study in Sweden randomised 30 adults to endurance exercise, resistance exercise or no exercise (10 each) and measured blood levels of MOTS-c and humanin; its authors reported that those levels were “not correlated to fitness outcomes”. Neither study gave MOTS-c to anyone.

The registered trial. No published study has given MOTS-c to people (PubMed and ClinicalTrials.gov, 21 November 2026). One trial is registered: NCT07505745, a phase 2a, randomised, placebo-controlled trial planned for 120 adults with prediabetes and overweight or obesity. Its primary outcomes are an insulin-sensitivity index and adverse events, not an energy measure. It is recruiting and has posted no results.

What regulators concluded. Reviewing MOTS-c in 2026, FDA staff found “a lack of evidence to evaluate the effectiveness” for its nominated uses, because the studies were “limited to in-vitro and in-vivo rodent models”, and wrote that “potential safety risks associated with the use of MOTS-c in humans are unknown”. FDA’s compounding page says MOTS-c products “may pose significant risk for immunogenicity for certain routes of administration”. HHS read the record differently: its 2026 policy appendix says “the available safety evidence points in one direction”, citing a trial of an unnamed MOTS-c analogue, a different molecule, that “reported no serious adverse events”. In sport, WADA names MOTS-c in class S4.4.1, metabolic modulators, prohibited at all times in the 2026 and 2027 Lists. More: the MOTS-c guide and MOTS-c claims and the evidence.

Humanin. Humanin is another peptide encoded in mitochondrial DNA. None of the eight humanin records that PubMed indexes as clinical trials gave it to people, and ClinicalTrials.gov lists no trial that gives it (both searched 21 November 2026). In the Swedish exercise study above, blood humanin rose after endurance exercise but not after resistance exercise. That shows when a natural level changes, not what giving humanin would do.

06What does “energy” mean in these studies?

In everyday speech, energy means how alert or how tired you feel. In these studies it is one of five things that can be measured.

1
ATP production in a muscle

ATP is the molecule that carries energy inside cells. One elamipretide study measured the peak rate at which a hand muscle made it, in 39 older adults.

2
Distance walked in six minutes

A test of exercise capacity. It was a main measure in the two elamipretide trials in patients.

3
A fatigue score

A questionnaire. The scores on this page come from patients with primary mitochondrial myopathy or Barth syndrome, not from healthy people.

4
Treadmill time and energy expenditure in mice

How long and how far a mouse runs, and how much energy its body uses. These are the MOTS-c measures.

5
A level in blood

NAD+ in blood, urine or blood cells, or the body’s own MOTS-c and humanin. A level is a lab value.

None of the five is the same as feeling more energetic. Only the fatigue scores ask people how they feel.

07What has not been shown about peptides and energy?

An effect on energy in healthy people

The elamipretide study in healthy older adults measured ATP production in one hand muscle after a single treatment. By day 7 there was no difference from placebo.

That mouse results carry over to people

No published study has given MOTS-c or humanin to people (PubMed and ClinicalTrials.gov, 21 Nov 2026). The registered MOTS-c trial has no results.

That a higher NAD+ level means more energy

In the 2018 trial of the precursor NR, NAD+ in blood cells was higher after NR, while energy expenditure, VO2max and treadmill time did not differ from placebo.

Long-term effects

The pooled trials of NAD+ and NR found a rise in a kidney marker with NAD+ that their authors said “warrants further evaluation”. FDA staff call the risks of MOTS-c in people unknown.

How these tiers are assigned: evidence grades. Related areas: MOTS-c research and longevity research.

This is a plain-English summary of public documents and studies, checked on 21 Nov 2026. It is not medical or legal advice.

RefSources

  1. U.S. Food and Drug Administration. Forzinity (elamipretide) injection, prescribing information, revised 9/2025 (NDA 215244; original approval 19 Sep 2025 per Drugs@FDA). Label, Drugs@FDA; read 21 Nov 2026. www.accessdata.fda.gov/drugsatfda_docs/label/2025/215244s000…
  2. Roshanravan B, Liu SZ, Ali AS, et al. [Randomised, placebo-controlled trial of a single treatment with elamipretide and muscle ATP production in 39 older adults.] PLoS One, 2021;16(7):e0253849. PMID 34264994 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/34264994/
  3. Karaa A, Bertini E, Carelli V, et al.; MMPOWER-3 Trial Investigators. [MMPOWER-3: phase 3, randomised, placebo-controlled trial of elamipretide in 218 adults with primary mitochondrial myopathy.] Neurology, 2023;101(3):e238–e252. PMID 37268435 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/37268435/
  4. Grant R, Berg J, Mestayer R, et al. [Pilot study of NAD+ and its metabolites in the plasma and urine of 11 healthy men given NAD+ or saline.] Front Aging Neurosci, 2019;11:257. PMID 31572171; full text PMC6751327 read 21 Nov 2026 for group sizes, funding and interests. pubmed.ncbi.nlm.nih.gov/31572171/
  5. Hamzah KA, Kurmasha YH, Elshabrawi MN, et al. [Systematic review and meta-analysis of four randomised placebo-controlled trials of NAD+ or nicotinamide riboside.] Eur J Clin Pharmacol, 2026;82(12):295. PMID 43040090 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/43040090/
  6. Martens CR, Denman BA, Mazzo MR, et al. [Randomised, placebo-controlled crossover trial of nicotinamide riboside in healthy adults aged 55 to 79: NAD+ in blood cells, energy expenditure and exercise capacity.] Nat Commun, 2018;9(1):1286. PMID 29599478; full text PMC5876407 read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/29599478/
  7. Gallagher C, Emmanuel OO. [PRISMA-guided systematic review of human and rodent studies of NAD+ and its precursors, January 2010 to October 2025.] Ageing Res Rev, 2026;116:103057. PMID 41655607 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/41655607/
  8. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol, 2021;22(2):119–141. PMID 33353981 (abstract and full text PMC7963035 read 21 Nov 2026). pmc.ncbi.nlm.nih.gov/articles/PMC7963035/
  9. Lee C, Zeng J, Drew BG, et al. [Description of MOTS-c, with cell and mouse experiments on metabolism.] Cell Metab, 2015;21(3):443–454. PMID 25738459; full text PMC4350682 read 21 Nov 2026 for group size and measures. pubmed.ncbi.nlm.nih.gov/25738459/
  10. Reynolds JC, Lai RW, Woodhead JST, et al. [MOTS-c in mice of different ages, and natural MOTS-c levels in exercising men.] Nat Commun, 2021;12(1):470. PMID 33473109; full text PMC7817689 read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/33473109/
  11. von Walden F, Fernandez-Gonzalo R, Norrbom J, et al. [Randomised study of blood humanin and MOTS-c levels after endurance or resistance exercise in 30 adults.] J Appl Physiol, 2021;131(3):1035–1042. PMID 34351816 (abstract read 21 Nov 2026). pubmed.ncbi.nlm.nih.gov/34351816/
  12. ClinicalTrials.gov. NCT07505745: phase 2a, randomised, placebo-controlled study of MOTS-c in adults with prediabetes and overweight or obesity. Registry record, first posted 1 Apr 2026; read 21 Nov 2026 (recruiting; no results posted). clinicaltrials.gov/study/NCT07505745
  13. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: MOTS-c-related bulk drug substances. Advisory committee briefing, 2026 (pp. 7, 30–31, 33); read 21 Nov 2026. www.fda.gov/media/193347/download
  14. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Web page, content current as of 22 Apr 2026; read 21 Nov 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-s…
  15. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, Appendix B. Policy document, 2026, undated in its text. hhs.gov returned 403 on 21 Nov 2026; read on the Internet Archive capture of 15 Nov 2026, the newest readable capture of the file (p. 10). www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement…
  16. World Anti-Doping Agency. Prohibited List 2026 (in force 1 Jan 2026) and Prohibited List 2027 (in force 1 Jan 2027), class S4.4.1. International Standard; both PDFs read 21 Nov 2026. The link opens the 2027 List. www.wada-ama.org/sites/default/files/2026-11/2027list_en_fin…
  17. Database searches run 21 Nov 2026: Drugs@FDA through openFDA (nadide, nicotinamide adenine dinucleotide, MOTS-c, humanin: no match; elamipretide: NDA 215244; control “semaglutide”: found); PubMed (MOTS-c and humanin with clinical-trial publication types: 5 and 8 records, none giving either to people); ClinicalTrials.gov (MOTS-c: NCT07505745 the only trial giving it; humanin: none). Registry and database queries. clinicaltrials.gov/search?intr=humanin

Plain-English summary of public sources, not legal or medical advice. Last checked 21 Nov 2026.

Questions

Is any of these compounds an approved medicine for energy or fatigue?

No. Elamipretide is approved in the US only as Forzinity, to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg, and research-grade material labelled SS-31 is not that medicine. Drugs@FDA lists no product containing NAD+, MOTS-c or humanin (21 November 2026).

Is NAD+ a peptide?

No. NAD+, nicotinamide adenine dinucleotide, is a coenzyme for the redox reactions of energy metabolism. It is built from nucleotides, not amino acids.

Has MOTS-c been tested in people?

Not as a given substance in any published study we found (PubMed and ClinicalTrials.gov, 21 November 2026). A placebo-controlled phase 2a trial is recruiting and has posted no results; earlier human studies measured the body’s own MOTS-c levels.

What did the SS-31 study in older adults measure?

Peak ATP production in a hand muscle, in 39 healthy adults aged 60 to 85 after a single treatment. The difference from placebo was borderline right after treatment and gone by day 7, and resistance to fatigue did not change.

What did the nicotinamide riboside trial measure besides NAD+ levels?

Energy expenditure, VO2max and treadmill time to exhaustion, in 24 healthy adults aged 55 to 79. None differed from placebo, although NAD+ in blood cells was higher after NR. NR is a different molecule from NAD+.

Is MOTS-c allowed in sport?

No. WADA names MOTS-c in class S4.4.1, metabolic modulators, prohibited at all times in the 2026 and 2027 Lists.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page